AMLN (DIABETES DRUGS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tonyt who wrote (423)	8/17/1997 6:28:00 PM
From: tonyt	of 2173

Reuters: SAN DIEGO, Aug 15 (Reuter) - Amylin Pharmaceuticals Inc said an initial Phase III study showed its diabetes drug candidate, pramlintide, improved metabolic control in people with Type 1 diabetes. Metabolic benefits included improved glucose control without increased risk of hypoglycemia and improved weight control and cholesterol profiles. Pramlintide is a synthetic analog of the human hormone amylin which is deficient in patients with diabetes who use insulin.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next